Tag: Y-90

radioembolization

Radioembolization with Y-90 now “a versatile treatment option” for HCC patients...

As presented at the Global Embolization Oncology Symposium Technologies (GEST) 2020 meeting (4–6 September, virtual), Robert Lewandowski discusses the evolution of radioembolization with Yttrium-90...
Y-90

SIR-Spheres Y-90 resin microspheres meet drug registration requirements in China

Sirtex Medical and its shareholders, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) have been issued a “Notice of Drug Clinical Trial Approval” by...
Y-90

Sirtex Medical completes enrollment of landmark US RESiN registry

Sirtex Medical reports that enrollment in the US RESiN registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for...
radioembolization

Novel use of Y-90 radioembolization could transform prostate cancer treatment

In an entirely new endeavour for Yttrium-90 (Y-90) radioembolization, investigators from Northwestern University, Chicago, USA, have used the technique for the treatment of prostate...
SIROS

Sirtex Medical launches SIROS system for SIR-Spheres resin microspheres delivery

A new system designed to deliver Yttrium-90 (Y-90) resin microspheres during targeted liver cancer therapies, SIROS (Sirtex) has launched commercially. A company press release states:...
Hepatology

Radioembolization paper publication a “landmark moment” for IR-Hepatology collaboration

The cover of June’s edition of the Journal of Hepatology featured a paper on transarterial radioembolization for the treatment of hepatocellular carcinoma (HCC). Publication...
ablation

Ablation cheaper than Y-90 or TACE for the treatment of hepatocellular...

Ablation costs are significantly less than those of transarterial chemoembolization (TACE) and Yttrium-90 (Y-90), according to a comparative cost analysis of the three...
NHS

SIRT approved for routine commissioning on the NHS

National Health Service (NHS) England have announced that selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) microspheres will now be routinely commissioned for NHS...

Y-90 radioembolization in hepatocellular carcinoma: “Liver function is key”

Jens Ricke (Department of Radiology, University Hospital LMU Munich, Germany) presented the latest evidence about Y-90 radioembolization in hepatocellular carcinoma (HCC) at the 2019...
Hepatology

Radiation segmentectomy offers new treatment option for liver cancer

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

MIM software receives US FDA 510(k) clearance for post-treatment dosimetry of...

Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...

Same day Y-90 treatment could become paradigm of the future

While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing...

New data show SIRT does not prolong overall survival in metastatic...

The FOXFIRE, SIRFLOX and FOXFIRE Global randomised studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer with selective internal radiotherapy (SIRT)...

The role of Y-90 radioembolization for cholangiocarcinoma

Y-90 radioembolization is a promising locoregional therapy for a devastating disease with few available treatment options. Ongoing and future clinical trials will help to...

Using Y-90 to achieve bariatric artery radioembolization

Nearly 10 years have passed since Aravind Arepally et al published data from the first gastric artery chemoembolization preclinical trials for the treatment of...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...

BTG and Mirada Medical announce CE mark certification for Simplicit90Y dosimetry...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...